Articles and whitepapers related to the PEVIVA products

Literature

Showing 676 of filtered documents

Metformin in the management of non-alcoholic fatty liver disease – current evidence and future perspectives

JJ Flores-Estrada, L J Pinto-García, N Nájera-García, O A Marché-Fernández, F J Cáceres-Carranza

Cardiovascular metabolism sciences; 2025

Severity of MASH Activity by Iron-Corrected MRI Predicts Insulin Resistance and Cardiometabolic Risk in Type 2 Diabetes

AO Rocha, S Kalavalapalli, E G Leiva, D Barb, F Bril, S A Marangi, H B Thomaides-Brears, J T Rosenberg, Ny Cuervo-Pardo, R Lomonaco, E V Saenz, A Sharma, K Cusi

The Journal of Clinical Endocrinology and Metabolism; 2026

Cytokeratin 18 fragment is associated with steatosis-associated fibrosis estimator score and lipid in patients with steatotic liver disease

T Ichikawa, Si Miuma, M Yamashima, S Yamamichi, M Koike, Y Nakano, H Yajima, O Miyazaki, T Ikeda, T Okamura, N Komatsu, M Yoshino, H Miyaaki

World Journal of Hepatology; 2025:110698

Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial

L Cristoferi, D D’Amato, C Maino, D Bernasconi, M E Dinelli, S M I Malandrin, F Facciotti, M M Festa, A Gerussi, E Rossi, F Malinverno, P Tettamanti, M E Cazzaniga, R Corso, D Ippolito, S Galimberti, P Invernizzi, M Carbone

BMJ Open; 2026:106630

Blood metabolic panels for identifying significant fibrosis and inflammation in patients with MASLD

Y Huang, J Li, S Song, B Du, Y Cao, Y Wang, H Fu, T Zhou, S Yu, Y Liu, K Wang, Z Cao, X Guo, C Xie, Q Xie

Cell Reports Medicine; 2026:102522

Serum Levels of Candida albicans 65-kDa Mannoprotein (CaMp65p) Correlate with Liver Disease in Patients with Alcohol Use Disorder

JT Schnabl, S Sandini, P Stärkel, P Hartmann

Microorganism; 2025:2458

A Phase 2a Trial of Myeloperoxidase Inhibitor Mitiperstat in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis

J Armisen, A Flor, J Eriksson, K Nelander, C S Bhattacharya, M Sunnåker, D Carter, M Trebski, E Gårdmark, M Aurell, C Whatling, B Challis, U Vespasiani-Gentilucci; COSMOS Investigators

Liver International; 2025:70406

Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH

LM Nitze, V Ratziu, A J Sanyal, V W-S Wong, C Balendran, J Fleckner, M S Kjær, N Kraup, Q M Anstee

Alimentary Pharmacology & Therapeutics; 2026:396-404

Due to rising demand, counterfeit M30 Apoptosense® ELISA and M65® ELISA kits have entered the market. These unauthorized products report inaccurate U/L values and are not equivalent to certified VLVbio assays. VLVbio’s Keratin-18 assays are CE-IVD marked under EU regulations. M30®, Apoptosense®, M65®, and EpiDeath® are registered trademarks of VLVbio and must not be used unlawfully. · · ·

Due to rising demand, counterfeit M30 Apoptosense® ELISA and M65® ELISA kits have entered the market. These unauthorized products report inaccurate U/L values and are not equivalent to certified VLVbio assays. VLVbio’s Keratin-18 assays are CE-IVD marked under EU regulations. M30®, Apoptosense®, M65®, and EpiDeath® are registered trademarks of VLVbio and must not be used unlawfully. · · ·